Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease

Biochemistry

Volumn 43, Issue 38, 2004, Pages 12141-12151

  Clemente, José C ^b   Moose, Rebecca E ^a   Hemrajani, Reena ^a   Whitford, Lisa R S ^a   Govindasamy, Lakshmanan ^a   Reutzel, Robbie ^a   McKenna, Robert ^a   Agbandje McKenna, Mavis ^a   Goodenow, Maureen M ^a   Dunn, Ben M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; CATALYSIS; CRYSTAL STRUCTURE; DYNAMICS;

BINDING CAVITY; INHIBITOR BINDING; PROTEASE;

VIRUSES;

INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; BIOACCUMULATION; DIMERIZATION; ENZYME ACTIVE SITE; ENZYME ANALYSIS; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN DATA BANK; STRUCTURE ANALYSIS; VIRUS ISOLATION; VIRUS RESISTANCE;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DIMERIZATION; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; HYDROGEN BONDING; HYDROPHOBICITY; INDINAVIR; KINETICS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; PROTEIN STRUCTURE, TERTIARY; THERMODYNAMICS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 4644353680     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi049459m     Document Type: Article

References (57)

1. Velazquez-Campoy, A., Vega, S., and Freire, E. (2002) Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes, Biochemistry 41, 8613-8619.
2. Towler, E. M., Thompson, S. K., Tomaszek, T., and Debouck, C. (1997) Identification of a loop outside the active site cavity of the human immunodeficiency virus proteases which confers inhibitor specificity, Biochemistry 36, 5128-5133.
3. Swairjo, M. A., Towler, E. M., Debouck, C., and Abdel-Meguid, S. S. (1998) Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease, Biochemistry 37, 10928-10936.
4. Smidt, M. L., Potts, K. E., Tucker, S. P., Blystone, L., Stiebel, T. R., Jr., Stallings, W. C., McDonald, J. J., Pillay, D., Richman, D. D., and Bryant, M. L. (1997) A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A, Antimicrob. Agents Chemother. 41, 515-522.
5. Olsen, D. B., Stahlhut, M. W., Rutkowski, C. A., Schock, H. B., van Olden, A. L., and Kuo, L. C. (1999) Nonactive site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors, J. Biol. Chem. 274, 23699-23701.
6. Hoog, S. S., Towler, E. M., Zhao, B., Doyle, M. L., Debouck, C., and Abdel-Meguid, S. S. (1996) Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity, Biochemistry 35, 10279-10286.
7. Wlodawer, A., and Gustchina, A. (2000) Structural and biochemical studies of retroviral proteases, Biochim. Biophys. Acta 1477, 16-34.
8. Tomasselli, A. G., and Heinrikson, R. L. (2000) Targeting the HIV-protease in AIDS therapy: A current clinical perspective, Biochim. Biophys. Acta 1477, 189-214.
9. Dunn, B. M. (2002) Anatomy and pathology of HIV-1 peptidase, Essays Biochem. 38, 113-127.
10. Molla, A., Korneyeva, M., Gao, Q., Vasavanonda, S., Schipper, P. J., Mo, H. M., Markowitz, M., Chernyavskiy, T., Niu, P., Lyons, N., Hsu, A., Granneman, G. R., Ho, D. D., Boucher, C. A., Leonard, J. M., Norbeck, D. W., and Kempf, D. J. (1996) Ordered accumulation of mutations in HIV protease confers resistance to ritonavir, Nat. Med. 2, 760-766.
11. Para, M. F., Glidden, D. V., Coombs, R. W., Collier, A. C., Condra, J. H., Craig, C., Bassett, R., Leavitt, R., Snyder, S., McAuliffe, V., and Boucher, C. (2000) Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333, J. Infect. Dis. 182, 733-743.
12. Zolopa, A. R., Shafer, R. W., Warford, A., Montoya, J. G., Hsu, P., Katzenstein, D., Merigan, T. C., and Efron, B. (1999) HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed, Ann. Intern. Med. 131, 813-821.
13. Condra, J. H., Petropoulos, C. J., Ziermann, R., Schleif, W. A., Shivaprakash, M., and Emini, E. A. (2000) Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy, J. Infect. Dis. 182, 758-765.
14. Patick, A. K., Duran, M., Cao, Y., Shugarts, D., Keller, M. R., Mazabel, E., Knowles, M., Chapman, S., Kuritzkes, D. R., and Markowitz, M. (1998) Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir, Antimicrob. Agents Chemother. 42, 2637-2644.
15. Ido, E., Man, H. P., Kezdy, F. J., and Tang, J. (1991) Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S, J. Biol. Chem. 266, 24359-24366.
16. Goodenow, M. M., Bloom, G., Rose, S. L., Pomeroy, S. M., O'Brien, P. O., Perez, E. E., Sleasman, J. W., and Dunn, B. M. (2002) Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease, Virology 292, 137-149.
17. Wain-Hobson, S., Sonigo, P., Danos, O., Cole, S., and Alizon, M. (1985) Nucleotide sequence of the AIDS virus, LAV, Cell 40, 9-17.
18. Clemente, J. C., Hemrajani, R., Blum, L. E., Goodenow, M. M., and Dunn, B. M. (2003) Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N, Biochemistry 42, 15029-15035.
19. Dunn, B. M., Gustchina, A., Wlodawer, A., and Kay, J. (1994) Subsite preferences of retroviral proteinases, Methods Enzymol. 241, 254-278.
20. Bhatt, D., and Dunn, B. M. (2000) Chimeric aspartic proteinases and active site binding, Bioorg. Chem. 28, 374-393.
21. Otwinowski, Z., and Minor, W. (1997) in Macromolecular Crystallography, Part A, pp 307-326.
22. Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Crystallography and NMR system: A new software suite for macromolecular structure determination, Acta. Crystallogr., Sect. D 54 (Part 5), 905-921.
23. Jones, T. A., Zou, J. Y., Cowan, S. W., and Kjeldgaard, M. (1991) Improved methods for building protein models in electron-density maps and the location of errors in these models, Acta Crystallogr., Sect. A 47, 110-119.
24. DeLano, W. L. (2002) DeLano Scientific, San Carlos, CA.
25. Keil, M., Exner, T., and Brickmann, J. (1998) Characterisation of protein-ligand interfaces: Separating surfaces, J. Mol. Model. 4, 335-339.
26. Exner, T., Keil, M., Moeckel, G., and Brickmann, J. (1998) Identification of substrate channels and protein cavities, J. Mol. Model. 4, 340-343.
27. Lin, Y., Lin, X., Hong, L., Foundling, S., Heinrikson, R. L., Thaisrivongs, S., Leelamanit, W., Raterman, D., Shah, M., Dunn, B. M., and et al. (1995) Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: Relationship to drug resistance, Biochemistry 34, 1143-1152.
28. Muzammil, S., Ross, P., and Freire, E. (2003) A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance, Biochemistry 42, 631-638.
29. Wilson, S. I., Phylip, L. H., Mills, J. S., Gulnik, S. V., Erickson, J. W., Dunn, B. M., and Kay, J. (1997) Escape mutants of HIV-1 proteinase: Enzymic efficiency and susceptibility to inhibition, Biochim. Biophys. Acta 1339, 113-125.
30. Condra, J. H., Holder, D. J., Schleif, W. A., Blahy, O. M., Danovich, R. M., Gabryelski, L. J., Graham, D. J., Laird, D., Quintero, J. C., Rhodes, A., Robbins, H. L., Roth, E., Shivaprakash, M., Yang, T., Chodakewitz, J. A., Deutsch, P. J., Leavitt, R. Y., Massari, F. E., Mellors, J. W., Squires, K. E., Steigbigel, R. T., Teppler, H., and Emini, E. A. (1996) Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor, J. Virol. 70, 8270-8276.
31. Dronda, F., Casado, J. L., Moreno, S., Hertogs, K., Garcia-Arata, I., Antela, A., Perez-Elias, M. J., Ruiz, L., and Larder, B. (2001) Phenotypic cross-resistance to nelfinavir: The role of prior antiretroviral therapy and the number of mutations in the protease gene, AIDS Res. Hum. Retroviruses 17, 211-215.
32. Hertogs, K., Bloor, S., De Vroey, V., van Den Eynde, C., Dehertogh, P., van Cauwenberge, A., Sturmer, M., Alcorn, T., Wegner, S., van Houtte, M., Miller, V., and Larder, B. A. (2000) A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V, Antimicrob. Agents Chemother. 44, 568-573.
33. Lawrence, J., Schapiro, J., Winters, M., Montoya, J., Zolopa, A., Pesano, R., Efron, B., Winslow, D., and Merigan, T. C. (1999) Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons, J. Infect. Dis. 179, 1356-1364.
34. Wiegers, K., Rutter, G., Kottler, H., Tessmer, U., Hohenberg, H., and Krausslich, H. G. (1998) Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites, J. Virol. 72, 2846-2854.
35. Pettit, S. C., Moody, M. D., Wehbie, R. S., Kaplan, A. H., Nantermet, P. V., Klein, C. A., and Swanstrom, R. (1994) The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions, J. Virol. 68, 8017-8027.
36. Chen, E. (1994) Host strain selection for bacterial expression of toxic proteins, Methods Enzymol. 241, 29-46.
37. Deeks, S. G., Grant, R. M., Beatty, G. W., Horton, C., Detmer, J., and Eastman, S. (1998) Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure, AIDS 12, F97-F102.
38. Karmochkine, M., Si Mohamed, A., Piketty, C., Ginsburg, C., Raguin, G., Schneider-Fauveau, V., Gutmann, L., Kazatchkine, M. D., and Belec, L. (2000) The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients, Antiviral. Res. 47, 179-188.
39. Pazhanisamy, S., Stuver, C. M., Cullinan, A. B., Margolin, N., Rao, B. G., and Livingston, D. J. (1996) Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants, J. Biol. Chem. 271, 17979-17985.
40. Yoshimura, K., Kato, R., Yusa, K., Kavlick, M. F., Maroun, V., Nguyen, A., Mimoto, T., Ueno, T., Shintani, M., Falloon, J., Masur, H., Hayashi, H., Erickson, J., and Mitsuya, H. (1999) JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1, Proc. Natl. Acad. Sci. U.S.A. 96, 8675-8680.
41. Gatanaga, H., Suzuki, Y., Tsang, H., Yoshimura, K., Kavlick, M. F., Nagashima, K., Gorelick, R. J., Mardy, S., Tang, C., Summers, M. F., and Mitsuya, H. (2002) Amino acid substitutions in Gag protein at noncleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors, J. Biol. Chem. 277, 5952-5961.
42. Johnson, V. A., Brun-Vézinet, F., Clotet, B., Conway, B., D'Aquila, R. T., Demeter, L. M., Kuritzkes, D. R., Pillay, D., Schapiro, J. M., Telenti, A., and Richman, D. D. (2003) Drug resistance mutations in HIV-1, Top. HIV Med. 11, 215-221.
43. Hoffman, N. G., Schiffer, C. A., and Swanstrom, R. (2003) Covariation of amino acid positions in HIV-1 protease, Virology 314, 536-548.
44. Ohtaka, H., Schon, A., and Freire, E. (2003) Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations, Biochemistry 42, 13659-13666.
45. Munshi, S., Chen, Z., Yan, Y., Li, Y., Olsen, D. B., Schock, H. B., Galvin, B. B., Dorsey, B., and Kuo, L. C. (2000) An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease, Acta. Crystallogr., Sect. D 56 (Part 4), 381-388.
46. Babe, L. M., Rose, J., and Craik, C. S. (1995) Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation, Proc. Natl. Acad. Sci. U.S.A. 92, 10069-10073.
47. McPhee, F., Good, A. C., Kuntz, I. D., and Craik, C. S. (1996) Engineering human immunodeficiency virus 1 protease heterodimers as macromolecular inhibitors of viral maturation, Proc. Natl. Acad. Sci. U.S.A. 93, 11477-11481.
48. Gulnik, S. V., Suvorov, L. I., Liu, B., Yu, B., Anderson, B., Mitsuya, H., and Erickson, J. W. (1995) Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure, Biochemistry 34, 9282-9287.
49. Vega, S., Kang, L. W., Velazquez-Campoy, A., Kiso, Y., Amzel, L. M., and Freire, E. (2004) A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease, Proteins 55, 594-602.
50. Swairjo, M. A., Towler, E. M., Debouck, C., and Abdel-Meguid, S. S. (1998) Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease, Biochemistry 37, 10928-10936.
51. Stebbins, J., Towler, E. M., Tennant, M. G., Deckman, I. C., and Debouck, C. (1997) The 80's loop (residues 78-85) is important for the differential activity of retroviral proteases, J. Mol. Biol. 267, 467-475.
52. Maschera, B., Darby, G., Palu, G., Wright, L. L., Tisdale, M., Myers, R., Blair, E. D., and Furfine, E. S. (1996) Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex, J. Biol. Chem. 271, 33231-33235.
53. Shuman, C. F., Markgren, P. O., Hamalainen, M., and Danielson, U. H. (2003) Elucidation of HIV-1 protease resistance by characterization of interaction kinetics between inhibitors and enzyme variants, Antiviral Res. 58, 235-242.
54. Prater, A. J., Beardall, A., Ariyoshi, K., Churchill, D., Galpin, S., Clarke, J. R., Weber, J. N., and McClure, M. O. (2001) Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients, AIDS 15, 1493-1502.
55. Perno, C. F., Cozzi-Lepri, A., Balotta, C., Forbici, F., Violin, M., Bertoli, A., Facchi, G., Pezzotti, P., Cadeo, G., Tositti, G., Pasquinucci, S., Pauluzzi, S., Scalzini, A., Salassa, B., Vincenti, A., Phillips, A. N., Dianzani, F., Appice, A., Angarano, G., Monno, L., Ippolito, G., Moroni, M., and d'Arminio Monforte, A. (2001) Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy, J. Infect. Dis. 184, 983-991.
56. Palmer, S., Alaeus, A., Albert, J., and Cox, S. (1998) Drug susceptibility of subtypes A, B, C, D, and E human immunodeficiency virus type 1 primary isolates, AIDS Res. Hum. Retroviruses 14, 157-162.
57. Wallace, A. C., Laskowski, R. A., and Thornton, J. M. (1995) LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions, Protein Eng. 8, 127-134.